Combining full-dose BRAF-inhibition with downstream MEK-inhibition (e.g., dabrafenib plus trametinib) efficiently mitigates detrimental paradoxical activation of the MAPK-pathway, which significantly decreases the incidence of secondary neoplasms. Here, BRAF is linked to neoplasm.